PWM
BMRN icon

Parkworth Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Parkworth Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$110 Sell
2
-2
-50% -$118 ﹤0.01% 1103
2025
Q1 		$283 Buy
4
+2
+100% +$135 ﹤0.01% 615
2024
Q4 		$131 Buy
+2
New +$134 ﹤0.01% 905

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parkworth Wealth Management's BMRN Position: Q2 2025 in Review

Parkworth Wealth Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 50% in Q2 2025, selling an estimated $118 and leaving 2 shares worth $110. The position accounts for ﹤0.01% of the portfolio, ranked #1103.

Parkworth Wealth Management first reported a position in BMRN in Q4 2024 and has held it in 3 quarters since. The position peaked at $283 in Q1 2025. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Parkworth Wealth Management held 2 shares of BioMarin Pharmaceuticals worth $110 as of Q2 2025.
  • Parkworth Wealth Management sold 2 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $118.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #1103 holding.
  • Parkworth Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Parkworth Wealth Management's BioMarin Pharmaceuticals position peaked at $283 in Q1 2025.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.